Literature DB >> 27440861

The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.

Hoa Q Nguyen1, Ernesto Callegari2, R Scott Obach2.   

Abstract

Major circulating drug metabolites can be as important as the drugs themselves in efficacy and safety, so establishing methods whereby exposure to major metabolites following administration of parent drug can be predicted is important. In this study, imipramine, a tricyclic antidepressant, and its major metabolite desipramine were selected as a model system to develop metabolite prediction methods. Imipramine undergoes N-demethylation to form the active metabolite desipramine, and both imipramine and desipramine are converted to hydroxylated metabolites by the polymorphic enzyme CYP2D6. The objective of the present study is to determine whether the human pharmacokinetics of desipramine following dosing of imipramine can be predicted using static and dynamic physiologically-based pharmacokinetic (PBPK) models from in vitro input data for CYP2D6 extensive metabolizer (EM) and poor metabolizer (PM) populations. The intrinsic metabolic clearances of parent drug and metabolite were estimated using human liver microsomes (CYP2D6 PM and EM) and hepatocytes. Passive diffusion clearance of desipramine, used in the estimation of availability of the metabolite, was predicted from passive permeability and hepatocyte surface area. The predicted area under the curve (AUCm/AUCp) of desipramine/imipramine was 12- to 20-fold higher in PM compared with EM subjects following i.v. or oral doses of imipramine using the static model. Moreover, the PBPK model was able to recover simultaneously plasma profiles of imipramine and desipramine in populations with different phenotypes of CYP2D6. This example suggested that mechanistic PBPK modeling combined with information obtained from in vitro studies can provide quantitative solutions to predict in vivo pharmacokinetics of drugs and major metabolites in a target human population.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27440861     DOI: 10.1124/dmd.116.071639

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Variability in Human In Vitro Enzyme Kinetics.

Authors:  Christopher R Gibson; Ying-Hong Wang; Ninad Varkhede; Bennett Ma
Journal:  Methods Mol Biol       Date:  2021

2.  Pharmacokinetics, Tissue Distribution and Excretion of a Novel Diuretic (PU-48) in Rats.

Authors:  Zhi-Yuan Zhang; Hua Zhang; Dan Liu; Ying-Yuan Lu; Xin Wang; Pu Li; Ya-Qing Lou; Bao-Xue Yang; Ya-Xin Lou; Chuang Lu; Qiang Zhang; Guo-Liang Zhang
Journal:  Pharmaceutics       Date:  2018-08-08       Impact factor: 6.321

3.  Metabolites of alectinib in human: their identification and pharmacological activity.

Authors:  Mika Sato-Nakai; Kosuke Kawashima; Toshito Nakagawa; Yukako Tachibana; Miyuki Yoshida; Kenji Takanashi; Peter N Morcos; Martin Binder; David J Moore; Li Yu
Journal:  Heliyon       Date:  2017-07-10

4.  Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model.

Authors:  Ernesto Callegari; Manthena V S Varma; R Scott Obach
Journal:  Clin Transl Sci       Date:  2020-02-04       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.